Small Stocks, Big Money™

Gorilla Technology Group (Nasdaq: GRRR) has officially closed its At-The-Market (ATM) program, reinforcing its commitment to protecting shareholder value and preventing dilution. This follows the company's recent share buyback initiative, signaling confidence in its financial strength and long-term growth trajectory. Chairman & CEO Jay Chandan emphasized Gorilla's disciplined strategy, focusing on execution, revenue expansion, and investor returns. With a strong AI-driven technology portfolio, the company remains dedicated to innovation across security, smart cities, and IoT solutions.

Alliance Entertainment (Nasdaq: AENT) secured an exclusive home entertainment licensing deal with Paramount Pictures, solidifying its leadership in physical media distribution. For the second quarter of fiscal year 2025, the company reported double-digit growth in key categories, with vinyl record sales up 12% year-over-year to $109 million and physical movie sales jumping 23% to $86 million, fueled by demand for premium formats like 4K UHD and collectible SteelBooks. Additionally, Alliance’s Handmade by Robots collectible figures have debuted at Walmart, further expanding the brand’s retail presence and tapping into the growing pop culture collectibles market. With strategic partnerships, strong sales momentum, and operational efficiencies in place, Alliance is poised for a robust second half of the fiscal year.

OS Therapies (NYSE American: OSTX) initiated commercial manufacturing of OST-HER2, its immunotherapy for preventing recurrent lung metastatic osteosarcoma, as it prepares for a Biologics Licensing Authorization (BLA) filing with the FDA. The company is organizing additional Phase 2b trial data ahead of an FDA meeting, with the goal of securing accelerated or conditional approval. OST-HER2 has received multiple FDA designations, including fast-track and orphan drug status, positioning OS Therapies for a potential breakthrough in osteosarcoma treatment.

VSee Health (Nasdaq: VSEE) has been selected by a top-five kidney care provider to integrate its telehealth workflow into the provider’s Oracle Health (Cerner) EHR system. The partnership has already driven an 88% increase in telehealth call completion rates, demonstrating VSee’s ability to improve efficiency and patient outcomes in specialized healthcare. Under the $200K enterprise contract, the deal positions VSee for further expansion as telehealth adoption accelerates. With a scalable, AI-powered platform and a growing market presence, VSee is well-positioned to capitalize on the booming digital health sector.